Putting a price tag on novel autologous cellular therapies

Cytotherapy

Volumn 18, Issue 8, 2016, Pages 1056-1061

  Abou El Enein, Mohamed ^a   Bauer, Gerhard ^b   Medcalf, Nicholas ^c   Volk, Hans Dieter ^a   Reinke, Petra ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c LOUGHBOROUGH UNIVERSITY   (United Kingdom)

Author keywords

adoptive T cell therapy; commercialization; cost of goods; good manufacturing practice; immunotherapy; market adoption; price; regulation; reimbursement; scale up

Indexed keywords

ADOPTIVE IMMUNOTHERAPY; ADOPTIVE TRANSFER; ARTICLE; AUTOTRANSPLANTATION; CELL THERAPY; GENE THERAPY; GOOD MANUFACTURING PRACTICE; HEALTH CARE COST; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOCOMPROMISED PATIENT; INVESTMENT; NONHUMAN; PRIORITY JOURNAL; REIMBURSEMENT; SCALE UP; T LYMPHOCYTE; BIOLOGICAL THERAPY; CELL ENGINEERING; COMMERCIAL PHENOMENA; ECONOMICS; EXPERIMENTAL THERAPY; PROCEDURES; TRANSPLANTATION;

CELL ENGINEERING; CELL- AND TISSUE-BASED THERAPY; COMMERCE; HUMANS; IMMUNOTHERAPY, ADOPTIVE; T-LYMPHOCYTES; THERAPIES, INVESTIGATIONAL; TRANSPLANTATION, AUTOLOGOUS;

EID: 84974815570     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2016.05.005     Document Type: Article

References (30)

1. [1] Leen, A.M., Bollard, C.M., Mendizabal, A.M., Shpall, E.J., Szabolcs, P., Antin, J.H., et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 121 (2013), 5113–5123.
2. [2] Gerdemann, U., Katari, U.L., Papadopoulou, A., Keirnan, J.M., Craddock, J.A., Liu, H., et al. Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther 21 (2013), 2113–2121.
3. [3] Gottschalk, S., Rooney, C.M., Adoptive T-cell immunotherapy. Current topics in microbiology and immunology, vol. 391, 2015, 427–454.
4. [4] Brestrich, G., Zwinger, S., Fischer, A., Schmück, M., Röhmhild, A., Hammer, M.H., et al. Adoptive T-cell therapy of a lung transplanted patient with severe CMV disease and resistance to antiviral therapy. Am J Transplant 9 (2009), 1679–1684.
5. [5] Fishman, J.A., Infection in solid-organ transplant recipients. N Engl J Med 357 (2007), 2601–2614.
6. [6] Husain, S., Pietrangeli, C.E., Zeevi, A., Delayed onset CMV disease in solid organ transplant recipients. Transpl Immunol 21 (2009), 1–9.
7. [7] Razonable, R.R., Humar, A., Cytomegalovirus in solid organ transplantation. Am J Transplant 13:Suppl. 4 (2013), 93–106.
8. [8] Razonable, R.R., Antiviral drugs for viruses other than human immunodeficiency virus. Mayo Clin Proc 86 (2011), 1009–1026.
9. [9] Jain, N.A., Lu, K., Ito, S., Muranski, P., Hourigan, C.S., Haggerty, J., et al. The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation—implications for preventative treatment approaches. Cytotherapy 16 (2014), 927–933.
10. [10] Saglio, F., Hanley, P.J., Bollard, C.M., The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care. Cytotherapy 16 (2014), 149–159.
11. [11] The European Commission, Commission directive 2003/94/EC laying down the principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal products for human use. Off J Eur Union 13 (2003), 22–26 http://ec.europa.eu/health/files/eudralex/vol-1/dir_2003_94/dir_2003_94_en.pdf.
12. [12] EudraLex, EudraLex—Volume 4 Good manufacturing practice (GMP) Guidelines. http://ec.europa.eu/health/documents/eudralex/vol-4/index_en.htm, 2009.
13. [13] Abou-El-Enein, M., Römhild, A., Kaiser, D., Beier, C., Bauer, G., Volk, H.-D., et al. Good Manufacturing Practices (GMP)manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. Cytotherapy 15 (2013), 362–383.
14. [14] Hourd, P., Ginty, P., Chandra, A., Williams, D.J., Manufacturing models permitting roll out/scale out of clinically led autologous cell therapies: regulatory and scientific challenges for comparability. Cytotherapy 16 (2014), 1033–1047.
15. [15] Abou-El-Enein, M., Bauer, G., Reinke, P., The business case for cell and gene therapies. Nat Biotechnol 32 (2014), 1192–1193.
16. [16] OCTANE, “See How” Octane Technology can impact your goals. http://octaneco.com/octane-download.pdf.
17. [17] Bajgain, P., Mucharla, R., Wilson, J., Welch, D., Anurathapan, U., Liang, B., et al. Optimizing the production of suspension cells using the G-Rex “M” series. Mol Ther Methods Clin Dev, 1, 2014, 14015.
18. [18] de Wilde, S., Veltrop-Duits, L., Hoozemans-Strik, M., Ras, T., Blom-Veenman, J., Guchelaar, H.-J., et al. Hurdles in clinical implementation of academic Advanced Therapy Medicinal Products: a national evaluation. Cytotherapy 18:6 (2016), 797–805, 10.1016/j.jcyt.2016.02.010.
19. [19] Cuende, N., Boniface, C., Bravery, C., Forte, M., Giordano, R., Hildebrandt, M., et al. The puzzling situation of hospital exemption for advanced therapy medicinal products in Europe and stakeholders’ concerns. Cytotherapy 16 (2014), 1597–1600.
20. [20] Hall, A.K., Carlson, M.R., The current status of orphan drug development in Europe and the US. Intractable Rare Dis Res 3 (2014), 1–7.
21. [21] Abou-El-Enein, M., Bauer, G., Reinke, P., Renner, M., Schneider, C.K., A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV. Trends Mol Med 20 (2014), 632–642.
22. [22] Blasimme, A., Rial-Sebbag, E., Regulation of cell-based therapies in europe: current challenges and emerging issues. Stem Cells Dev 22 (2013), 14–19.
23. [23] Maciulaitis, R., D'Apote, L., Buchanan, A., Pioppo, L., Schneider, C.K., Clinical development of advanced therapy medicinal products in Europe: evidence that regulators must be proactive. Mol Ther 20 (2012), 479–482.
24. [24] Abou-El-Enein, M., Schneider, C.K., Deciphering the EU clinical trials regulation. Nat Biotechnol 34 (2016), 231–233.
25. [25] The European Commission, Summary of the responses to the targeted stakeholder consultation on the development of Guidelines on Good Manufacturing Practice for Advanced Therapy Medicinal Products pursuant to Article 5 of Regulation 1394/2007. http://ec.europa.eu/health/files/advtherapies/2015_11_pc_gmp_atmp/2015_11_pc_gmp_atmp_summary.pdf, 2015.
26. [26] Srivastava, A., Mason, C., Wagena, E., Cuende, N., Weiss, D.J., Horwitz, E.M., et al. Part 1: defining unproven cellular therapies. Cytotherapy 18 (2016), 117–119.
27. [27] Abou-El-Enein, M., Bauer, G., Reinke, P., Gene therapy: a possible future standard for HIV care. Trends Biotechnol 33 (2015), 374–376.
28. [28] Cruz, C.R., Hanley, P.J., Liu, H., Torrano, V., Lin, Y.-F., Arce, J.A., et al. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy 12 (2010), 743–749.
29. [29] Hammer, M.H., Meyer, S., Brestrich, G., Moosmann, A., Kern, F., Tesfa, L., et al. HLA type-independent generation of antigen-specific T cells for adoptive immunotherapy. Eur J Immunol 35 (2005), 2250–2258.
30. [30] Hiwarkar, P., Gaspar, H.B., Gilmour, K., Jagani, M., Chiesa, R., Bennett-Rees, N., et al. Impact of viral reactivations in the era of pre-emptive antiviral drug therapy following allogeneic haematopoietic SCT in paediatric recipients. Bone Marrow Transplant 48 (2013), 803–808.